Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications.

Saved in:
Bibliographic Details
Title: Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications.
Authors: Kulkarni T; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Santiaguel J; Division of Pulmonary Medicine, Department of Medicine, Philippine General Hospital, Manila, Philippines.; Department of Medicine, Quirino Memorial Medical Center, Quezon City, Philippines., Aul R; Division of Respiratory Medicine, St George's University Hospitals NHS Foundation Trust, London, UK., Harnett M; Harnett Biostatistics Consulting, Stow, MA, USA., Krop J; PureTech Health, Boston, MA, USA., Chen MC; PureTech Health, Boston, MA, USA., Graham CS; PureTech Health, Boston, MA, USA., Maher TM; National Heart and Lung Institute, Imperial College London, London, UK.; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Source: ERJ open research [ERJ Open Res] 2025 Jul 21; Vol. 11 (4). Date of Electronic Publication: 2025 Jul 21 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: European Respiratory Society Country of Publication: England NLM ID: 101671641 Publication Model: eCollection Cited Medium: Print ISSN: 2312-0541 (Print) Linking ISSN: 23120541 NLM ISO Abbreviation: ERJ Open Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2312-0541
DOI:10.1183/23120541.01142-2024